 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | Iclusig (ponatinib) / Takeda, Otsuka, Incyte
New P1/2 trial: A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL) (clinicaltrials.gov) - Jan 16, 2024
P1/2, N=33, Not yet recruiting, Sponsor: University of Chicago
- | Blincyto (blinatumomab) / Astellas, Amgen
Trial completion date: SWOG-S1318: Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Oct 18, 2023
P2, N=53, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Oct 2023 --> Sep 2024
- | Xatmep (methotrexate oral solution) / Azurity Pharma, Nexlizet (bempedoic acid/ezetimibe) / Esperion Therap, Otsuka, Daiichi Sankyo
New trial: Drug Concentrations in Breast Milk and Prediction of Blood Levels of the Breastfed Infants (clinicaltrials.gov) - Sep 16, 2022
P=N/A, N=304, Recruiting, Sponsor: The Hospital for Sick Children
- | Blincyto (blinatumomab) / Astellas, Amgen
Trial completion date, Trial primary completion date: SWOG-S1318: Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Sep 7, 2022
P2, N=57, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Oct 2023 --> Sep 2024 Trial completion date: Jun 2023 --> Sep 2023 | Trial primary completion date: Jun 2023 --> Jun 2022
- | Blincyto (blinatumomab) / Astellas, Amgen
Trial completion date, Trial primary completion date: SWOG-S1318: Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jun 3, 2022
P2, N=58, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Jun 2023 --> Sep 2023 | Trial primary completion date: Jun 2023 --> Jun 2022 Trial completion date: Jun 2022 --> Jun 2023 | Trial primary completion date: Jun 2022 --> Jun 2023
- | hydroxychloroquine / Generic mfg., methotrexate / Generic mfg.
Journal: Expanded Table: Some conventional DMARDs for rheumatoid arthritis. (Pubmed Central) - Feb 8, 2022
Trial completion date: Jun 2022 --> Jun 2023 | Trial primary completion date: Jun 2022 --> Jun 2023 No abstract available
- | Blincyto (blinatumomab) / Astellas, Amgen
Enrollment closed: SWOG-S1318: Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Oct 22, 2021
P2, N=58, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
No abstract available Suspended --> Active, not recruiting
- | Blincyto (blinatumomab) / Astellas, Amgen
Trial suspension: SWOG-S1318: Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Feb 4, 2021
P2, N=58, Suspended, Sponsor: National Cancer Institute (NCI)
Suspended --> Active, not recruiting Recruiting --> Suspended
- | Blincyto (blinatumomab) / Astellas, Amgen
Trial primary completion date: SWOG-S1318: Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jan 7, 2021
P2, N=58, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Suspended Trial primary completion date: Jul 2021 --> Jun 2022
- | Otrexup (methotrexate) / Halozyme
Trial completion: Preventing Nephrotoxicity and Ototoxicity From Osteosarcoma Therapy (clinicaltrials.gov) - Mar 16, 2020
P2, N=13, Completed, Sponsor: Children's Hospital of Philadelphia
Trial primary completion date: Jul 2021 --> Jun 2022 Active, not recruiting --> Completed
- | Otrexup (methotrexate) / Halozyme, Rituxan (rituximab) / Roche
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: Chemotherapy and HAART to Treat AIDS-related Primary Brain Lymphoma (clinicaltrials.gov) - Sep 23, 2019
P2, N=12, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Recruiting --> Completed | N=28 --> 12 | Trial completion date: Jul 2021 --> Sep 2019 | Trial primary completion date: Jul 2020 --> Sep 2019
- | Blincyto (blinatumomab) / Astellas, Amgen
Enrollment change: SWOG-S1318: Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Sep 16, 2019
P2, N=58, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed | N=28 --> 12 | Trial completion date: Jul 2021 --> Sep 2019 | Trial primary completion date: Jul 2020 --> Sep 2019 N=44 --> 58
- | Otrexup (methotrexate) / Halozyme, Rituxan (rituximab) / Roche
Trial primary completion date: Chemotherapy and HAART to Treat AIDS-related Primary Brain Lymphoma (clinicaltrials.gov) - May 6, 2019
P2, N=28, Recruiting, Sponsor: National Cancer Institute (NCI)
N=44 --> 58 Trial primary completion date: Jul 2019 --> Jul 2020
- | Otrexup (methotrexate) / Halozyme, Rituxan (rituximab) / Roche
Trial primary completion date: Chemotherapy and HAART to Treat AIDS-related Primary Brain Lymphoma (clinicaltrials.gov) - Jul 21, 2017
P2, N=28, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jul 2019 --> Jul 2020 Trial primary completion date: Jul 2018 --> Jul 2019
- | Otrexup (methotrexate) / Halozyme
Enrollment closed, Enrollment change, Trial primary completion date: Preventing Nephrotoxicity and Ototoxicity From Osteosarcoma Therapy (clinicaltrials.gov) - Jul 6, 2017
P2, N=13, Active, not recruiting, Sponsor: Children's Hospital of Philadelphia
Trial primary completion date: Jul 2018 --> Jul 2019 Recruiting --> Active, not recruiting | N=24 --> 13 | Trial primary completion date: May 2017 --> Dec 2016
- Blincyto (blinatumomab) / Astellas, Amgen
Trial primary completion date: SWOG-S1318: Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Aug 8, 2016
P2, N=44, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting | N=24 --> 13 | Trial primary completion date: May 2017 --> Dec 2016 Trial primary completion date: Jul 2019 --> Jul 2021
- Otrexup (methotrexate) / Halozyme, Rituxan (rituximab) / Roche
Trial primary completion date: Chemotherapy and HAART to Treat AIDS-related Primary Brain Lymphoma (clinicaltrials.gov) - Jul 23, 2016
P2, N=28, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jul 2019 --> Jul 2021 Trial primary completion date: Jul 2016 --> Jul 2018
- Blincyto (blinatumomab) / Astellas, Amgen
Enrollment open: SWOG-S1318: Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jan 28, 2015
P2, N=44, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jul 2016 --> Jul 2018 Not yet recruiting --> Recruiting
- Otrexup (methotrexate) / Halozyme
Trial primary completion date: Preventing Nephrotoxicity and Ototoxicity From Osteosarcoma Therapy (clinicaltrials.gov) - Dec 13, 2014
P2, N=24, Recruiting, Sponsor: Children's Hospital of Philadelphia
Not yet recruiting --> Recruiting Trial primary completion date: May 2016 --> May 2017
- Blincyto (blinatumomab) / Astellas, Amgen
Trial initiation date: SWOG-S1318: Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Dec 5, 2014
P2, N=50, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: May 2016 --> May 2017 Initiation date: Aug 2014 --> Jan 2015
- Otrexup (methotrexate) / Halozyme, Rituxan (rituximab) / Roche
Trial primary completion date: Chemotherapy and HAART to Treat AIDS-related Primary Brain Lymphoma (clinicaltrials.gov) - Oct 23, 2014
P2, N=28, Recruiting, Sponsor: National Cancer Institute (NCI)
Initiation date: Aug 2014 --> Jan 2015 Trial primary completion date: Jul 2018 --> Jul 2016
- Otrexup (methotrexate) / Halozyme, Rituxan (rituximab) / Roche
Trial primary completion date: Chemotherapy and HAART to Treat AIDS-related Primary Brain Lymphoma (clinicaltrials.gov) - Oct 20, 2014
P2, N=28, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jul 2018 --> Jul 2016 Trial primary completion date: Dec 2014 --> Jul 2018
- Blincyto (blinatumomab) / Astellas, Amgen
New P2 trial: SWOG-S1318: Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov) - May 19, 2014
P2, N=50, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- Otrexup (methotrexate) / Halozyme
New P2 trial: Preventing Nephrotoxicity and Ototoxicity From Osteosarcoma Therapy (clinicaltrials.gov) - May 5, 2013
P2, N=24, Recruiting, Sponsor: Children's Hospital of Philadelphia
- Otrexup (methotrexate) / Halozyme, Rituxan (rituximab) / Roche
Enrollment change: Chemotherapy and HAART to Treat AIDS-related Primary Brain Lymphoma (clinicaltrials.gov) - Sep 11, 2012
P2, N=28, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Dec 2014 --> Jul 2018 N=18 --> 28